Scholar Rock's CEO on a big phase 3 readout coming later this year in SMA, myostatin inhibition for obesity, and more

Aug 9, 2024
1 min read

Jay Backstrom describes the company's approach of targeting the latent form of growth factors, the importance of the upcoming SAPPHIRE phase 3 readout, the rational for myostatin inhibition in obesity, and recent ASCO data.

Recent Posts

See All

ASCO 2025: PharmaMar presented data showing that the combo of Zepzelca and Tecentriq significantly improved survival as first-line maintenance therapy for extensive-stage small cell lung cancer

ASCO 2025: France based Transgene presented data for its personalized cancer vaccine in the adjuvant setting for HPV- head and neck cancer

ASCO 2025: Candel Therapeutics CEO Paul Peter Tak describes phase 3 prostate cancer data from the company's off-the-shelf, adeno delivered, cancer immunotherapy

Scholar Rock's CEO on a big phase 3 readout coming later this year in SMA, myostatin inhibition for obesity, and more

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight